Fertility and PCOS: Understanding Your Options

Introduction

Infertility is one of the most distressing consequences of PCOS for women who want to conceive. Because PCOS causes irregular or absent ovulation, natural conception can be difficult or impossible for many affected women. However, PCOS is one of the most treatable causes of infertility: with appropriate lifestyle modification and ovulation induction, the majority of women with PCOS can achieve pregnancy. This article outlines the fertility landscape for PCOS and the evidence-based treatment pathway.

How PCOS Affects Fertility

The primary fertility barrier in PCOS is anovulation. Without ovulation, there is no egg to fertilise. Ovulation in PCOS is disrupted by:

• Elevated LH:FSH ratio (from rapid GnRH pulsatility) — promotes thecal androgen production over follicle maturation
• Hyperinsulinaemia — amplifies androgen excess and impairs granulosa cell FSH responsiveness
• Androgen excess in follicular fluid — arrests follicle development
• preventing any single follicle from achieving dominance
• Multiple antral follicles "competing" — numerous small follicles develop but none ovulates

Even when periods do occur (often from breakthrough bleeding from anovulatory cycles, not true ovulatory menstruation

Lifestyle Modification: The First Step

For overweight and obese women with PCOS, weight loss of just 5–10% of body weight can restore ovulation in up to 50% of cases. Weight loss reduces hyperinsulinaemia, lowers androgen levels, restores GnRH pulsatility towards normal, and improves response to ovulation induction agents. Even lean women benefit from optimising dietary composition (low-GI, Mediterranean-style) and regular exercise to improve insulin sensitivity.

Lifestyle modification should be the first-line intervention before pharmacological ovulation induction in women with PCOS who are overweight. It also improves IVF outcomes if ART is eventually needed.

Ovulation Induction: Pharmacological Options

Letrozole — First-Line (ACOG, 2023 International PCOS Guideline)

Letrozole, an aromatase inhibitor, is now the preferred first-line agent for ovulation induction in PCOS. It works by transiently reducing estrogen levels, which releases negative feedback on the pituitary and causes an FSH rise to stimulate follicle development. Unlike clomiphene, letrozole:

• Has fewer anti-estrogenic effects on the endometrium (resulting in better endometrial receptivity)
• Produces predominantly mono-follicular ovulation (lower multiple pregnancy risk)
• Has higher cumulative live birth rates than clomiphene in PCOS (evidence from the PPCOS II trial and meta-analyses)
• Is administered orally for 5 days in the early follicular phase (Days 3–7)

Clomiphene Citrate — Second-Line

Clomiphene (a selective estrogen receptor modulator) was the traditional first-line agent for anovulatory PCOS for decades. It induces FSH release by blocking estrogen receptors in the hypothalamus. However, its anti-estrogenic effects thin the endometrial lining and thicken cervical mucus, reducing pregnancy rates relative to ovulation rates. Multiple pregnancy (especially twins) rates are higher than with letrozole (~8% vs ~3.4%).

Metformin — Adjunct

Metformin alone has modest evidence for restoring ovulation in PCOS through insulin sensitisation. It is less effective than letrozole as a standalone ovulation induction agent but may improve the response to letrozole or clomiphene when combined — particularly in insulin-resistant women. Metformin also reduces ovarian hyperstimulation syndrome (OHSS) risk in IVF.

Gonadotrophins (FSH Injections)

Injectable FSH is used when oral agents fail. It must be carefully monitored (ultrasound and blood estradiol) to prevent hyperstimulation and multiple pregnancy. Women with PCOS are particularly susceptible to OHSS due to their numerous antral follicles. Low-dose "step-up" protocols are recommended.

Laparoscopic Ovarian Surgery (Drilling)

Laparoscopic ovarian drilling (LOD) — puncturing multiple follicles on the ovary surface with cautery or laser — is an alternative for women who do not respond to oral agents. It lowers LH and androgen levels by destroying thecal tissue. Evidence shows it has equivalent efficacy to gonadotrophin therapy with lower multiple pregnancy risk and may be appropriate when serial gonadotrophin cycles are not feasible.

IVF — Third-Line

In vitro fertilisation is indicated when less invasive methods fail or when tubal, male factor, or other issues co-exist. PCOS women generally have excellent egg numbers for IVF (due to their antral follicle excess) but require careful ovarian stimulation protocols to minimise OHSS risk. GnRH antagonist protocols with freeze-all strategies (transferring frozen embryos in a subsequent unstimulated cycle) significantly reduce OHSS risk.

Psychological Aspects of Fertility Treatment in PCOS

Fertility treatment is emotionally demanding. Women with PCOS already carry a higher burden of anxiety and depression. Multiple treatment cycles, the uncertainty of outcome, and the visible signs of PCOS (hirsutism, weight challenges) compound psychological distress. Psychological support — individual therapy, peer support groups, and couples counselling — should be integrated into fertility care for PCOS.

References: 2023 International PCOS Guideline; Legro RS et al. (PPCOS II trial) NEJM 2014; ACOG Practice Bulletin on Ovulation Induction; Balen AH, Br J Obstet Gynaecol 2023.